- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03950427
PARQuit Smoking Cessation Intervention for Adults With Serious Mental Illness (PARQuit)
Study Overview
Status
Detailed Description
The purpose of this study is to learn more about how adults with serious mental illness respond to a smoking cessation program combining a game-based Physical activity, counseling for smoking cessation, and a medication (bupropion or NRT) for smoking cessation.
Study participants will receive counseling to quit smoking and a medication to help decrease cravings and withdrawal. Additionally, participants will be randomly selected to participate in either a game-based physical activity group or a game group where the participants sit to play the games.
Participants will be in this study for 12 weeks total. There are 3 assessment visits (2 hours each) at the beginning of the study, 6 weeks after starting, and at the end of the 12 weeks. There will be 8 30- minute counseling sessions during the 12 weeks. The hour-long videogame groups will be held 3 times a week for 12 weeks (36 sessions). Upon completion of the 12-week program, there will be a 1-2 hour group interview. The total time commitment is 48 hours over the course of the 12-week study.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Heather Leutwyler, PhD
- Phone Number: 415-514-1524
- Email: Heather.Leutwyler@ucsf.edu
Study Contact Backup
- Name: Erin Hubbard, MPH
- Phone Number: 415-502-7774
- Email: erin.hubbard@ucsf.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94143-0610
- Recruiting
- University of California, San Francisco
-
Contact:
- Heather Leutwyler, PhD
- Phone Number: 415-514-1524
- Email: Heather.Leutwyler@ucsf.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- A diagnosis of a SMI*
- 18 years and older
- Smoking at least five cigarettes per day for the past 6 months
- Willingness to set a quit date
- Not currently taking bupropion or using nicotine replacement therapy (NRT)
- Current participant in the residential or day treatment program at a Progress Foundation program with the intention to continue in the residential or day treatment program for at least the 12 week intervention period
Capacity to consent.
- SMI is characterized by the American Psychological Association as distinct conditions that require routine management, produce functional impairment, and interfere with quality of life. Individuals that typically meet the criteria of SMI have illnesses that include schizophrenia, schizoaffective disorder, psychotic disorders, major depressive disorders, bipolar disorders, and borderline personality disorder.
Exclusion Criteria:
- Currently pregnant or breastfeeding
- Diagnosis of seizure disorder, history of anorexia/bulimia, undergoing abrupt discontinuation of ethanol or sedatives, other conditions that increase seizure risk (e.g., arteriovenous malformation (AVM), severe head injury, central nervous system (CNS) tumor)
- use of Monoamine oxidase (MAO) inhibitors (concurrently or within 14 days of discontinuing either bupropion or the MAO inhibitor)
- Planning to become pregnant during the study period
- Previous participation in the videogame-based physical activity intervention.
- Known medical conditions or other physical problems that need special attention in an exercise program (e.g. prior myocardial infarction, uncontrolled hypertension, history of angioplasty, history of angina, use of nitroglycerin to treat angina)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: game-based Physical Activity Group
The game-based physical activity group, will play active games using the Kinect for Xbox 360 game system or outdoors in a public park. Each game group will be facilitated by the study coordinator, the principal investigator or other study staff. Participants in this group will also receive bupropion and counseling for smoking cessation. |
videogame-based physical activity
Bupropion
Other Names:
Counseling for smoking cessation
|
Placebo Comparator: Sedentary Videogame Group
The sedentary videogame group will play games while seated using the Xbox 360 game system (without the Kinect sensor) or seated outdoors in a public park. Each sedentary videogame group will be facilitated by study staff. Participants in this group will also receive bupropion and counseling for smoking cessation. |
Bupropion
Other Names:
Counseling for smoking cessation
sedentary videogame
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total number of videogame sessions attended
Time Frame: 12-weeks
|
Feasibility will be measured with a total count of sessions attended.
The graduate student researcher (GSR) will document participant attendance.
|
12-weeks
|
Total minutes of videogame sessions attended
Time Frame: 12-weeks
|
Feasibility will be measured with a sum of minutes attended.
The GSR will monitor and document the times when participants enter and leave the sessions.
|
12-weeks
|
Week-6 Self-report acceptability rankings of the videogames
Time Frame: administered at week 6
|
This internally developed acceptability questionnaire has 7 questions.
Three questions use a 1 to 5 scale with 1 indicating least acceptable and 5 indicating most acceptable, for a possible total range of 3-15.
The remaining open-ended questions are scored using qualitative thematic analysis.
|
administered at week 6
|
Week-12 Self-report acceptability rankings of the videogames -week 12
Time Frame: administered at week 12.
|
This internally developed acceptability questionnaire has 7 questions.
Three questions use a 1 to 5 scale with 1 indicating least acceptable and 5 indicating most acceptable, for a possible total range of 3-15.
The remaining open-ended questions are scored using qualitative thematic analysis.
Used to measure change from week-6 to week-12.
|
administered at week 12.
|
Tobacco reduction and abstinence
Time Frame: administered at week 6.
|
The investigators will ask about the number of cigarettes, even a puff, smoked in the past week (7-day abstinence) or use of any form of tobacco or alternative tobacco product e.g., e-cigarette or heat not burn.
Salivary cotinine levels will be measured to determine abstinence from smoking.
|
administered at week 6.
|
Tobacco reduction and abstinence
Time Frame: administered at week 12.
|
The investigators will ask about the number of cigarettes, even a puff, smoked in the past week (7-day abstinence) or use of any form of tobacco or alternative tobacco product e.g., e-cigarette or heat not burn.
Salivary cotinine levels will be measured to determine abstinence from smoking.
|
administered at week 12.
|
Baseline Brief Psychiatric Rating Scale (BPRS)
Time Frame: Baseline interview with the participant and observations of the participant's behavior over the previous 2-3 days.
|
The Semi-Structured Interview for Brief Psychiatric Rating Scale is completed by the PI or trained research staff and assesses the number and severity of psychiatric symptoms.
It consists of 24 items that are rated from 1 (not present) to 7 (extremely severe), and the items are summed for a total psychopathology score, with a possible range from 24-168 and a higher score indicating a higher severity of illness.
The score will be used to measure change between the baseline, 6-week, and 12-week time points.
|
Baseline interview with the participant and observations of the participant's behavior over the previous 2-3 days.
|
Week-6 Brief Psychiatric Rating Scale (BPRS)
Time Frame: interview at week-6 with the participant and observations of the participant's behavior over the previous 2-3 days.
|
The Semi-Structured Interview for Brief Psychiatric Rating Scale is completed by the PI or trained research staff and assesses the number and severity of psychiatric symptoms.
It consists of 24 items that are rated from 1 (not present) to 7 (extremely severe), and the items are summed for a total psychopathology score, with a possible range from 24-168 and a higher score indicating a higher severity of illness.
The score will be used to measure change between the baseline, 6-week, and 12-week time points.
|
interview at week-6 with the participant and observations of the participant's behavior over the previous 2-3 days.
|
Week-12 Brief Psychiatric Rating Scale (BPRS)
Time Frame: interview at week-12 with the participant and observations of the participant's behavior over the previous 2-3 days.
|
The Semi-Structured Interview for Brief Psychiatric Rating Scale is completed by the PI or trained research staff and assesses the number and severity of psychiatric symptoms.
It consists of 24 items that are rated from 1 (not present) to 7 (extremely severe), and the items are summed for a total psychopathology score, with a possible range from 24-168 and a higher score indicating a higher severity of illness.
The score will be used to measure change between the baseline, 6-week, and 12-week time points.
|
interview at week-12 with the participant and observations of the participant's behavior over the previous 2-3 days.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Heather Leutwyler, PhD, University of California, San Francisco
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Substance-Related Disorders
- Mental Disorders
- Tobacco Use Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Dopamine Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP2D6 Inhibitors
- Dopamine Uptake Inhibitors
- Bupropion
Other Study ID Numbers
- T29IP0235
- 22637 (Other Identifier: University of California, San Francisco)
- NCI-2022-02281 (Registry Identifier: NCI Clinical Trials Reporting Program (CTRP))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking Cessation
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
Nabi BiopharmaceuticalsNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco CessationUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Heidelberg UniversityPfizerTerminatedSmoking | Smoking Cessation | Tobacco Use CessationGermany
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
University of MiamiFlorida Department of HealthRecruitingSmoking Cessation | Tobacco Smoking | Tobacco Use CessationUnited States
-
University of VermontMayo Clinic; Alaska Native Tribal Health ConsortiumTerminatedSmoking | Smoking CessationUnited States
-
University of Wisconsin, MadisonCentiment LLCCompletedSmoking | Smoking CessationUnited States
-
Yale UniversityCompletedSmoking | Smoking CessationUnited States
-
Johns Hopkins UniversityMaryland Department of Health and Mental HygieneCompletedCOach2Quit TRIAL: Assessing a Prototype Personal Carbon Monoxide Monitor for Smoking Cessation (C2Q)Smoking | Smoking CessationUnited States
Clinical Trials on Videogame-based physical activity
-
Augusta UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Kansas... and other collaboratorsCompletedMental Disorders, SevereUnited States
-
Scientific Institute San RaffaeleCompleted
-
University Hospital of FerraraUniversità degli Studi di FerraraRecruitingChronic Kidney Disease Stage 5 on DialysisItaly
-
The University of Hong KongThe Hong Kong Council of Social ServiceCompleted
-
United States Naval Medical Center, San DiegoNaval Health Research CenterCompletedMajor Depressive DisorderUnited States
-
University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI)CompletedPhysical ActivityUnited States
-
Scientific Institute San RaffaeleIstituto Ortopedico GaleazziRecruiting
-
Nemours Children's ClinicCompletedObesity | Cardiovascular Disease
-
Rutgers, The State University of New JerseyTerminatedBreast Cancer | Resistance TrainingUnited States
-
Rigshospitalet, DenmarkUniversity of Copenhagen; Danish Cancer Society; Danish Child Cancer FoundationRecruitingPediatric CancerDenmark